Gelonghui, May 23丨Secoside (688338.SH) recently said during a survey receiving institutional investors that during the epidemic, the diagnosis and treatment activities of terminal hospitals in some regions of the country were drastically reduced, which led to a decline in the hospital's demand for testing related to the use of the company's products, which in turn had a certain impact on the main business. In 2023, the recovery of the company's instruments was growing significantly. At the same time, the SF-9200 fully automatic coagulation analyzer product was put on the market. Currently, the product has excellent performance in terms of testing speed, degree of automation, accuracy, etc., and has been put into use in many tertiary hospitals after completing installation and evaluation, and has received widespread praise from installed users.